Effects of personality on the association between paroxetine plasma concentration and response

Figures & data

Table 1 Demographic and clinical data of patients

	Entire cohort (n=62)	Responders (n=43)	Nonresponders (n=19)	P-value
Age, years	46.4±13.0	47.6±12.6	43.8±13.9	0.299
Sex (M:F)	22:40	13:30	9:10	0.194
MADRS, week
0	39.8±9.2	39.8±9.0	39.8±9.7	0.998
1	28.5±10.9	25.8±10.2	34.5±10.1	0.003**
2	20.3±11.7	17.9±10.9	25.8±11.8	0.013*
4	15.4±12.2	10.1±8.9	27.5±9.7	0.000**
6	13.2±12.8	6.1±5.5	29.4±9.6	0.000**
Concentration	64.7±45.0	53.8±42.6	89.5±41.3	0.003**
TCI
NS	17.3±4.5	17.8±4.3	16.1±4.9	0.168
HA	27.7±4.0	27.3±3.8	28.6±4.2	0.233
RD	13.8±3.3	14.1±3.4	13.2±3.0	0.321
P	3.7±1.7	3.5±1.6	4.0±2.0	0.286
SD	20.6±6.2	21.3±6.4	19.1±5.8	0.213
C	26.9±4.4	27.8±3.9	24.6±4.7	0.007**
ST	10.7±5.3	11.3±5.3	9.5±5.4	0.235

Notes:

* P<0.05;

** P<0.01.

Abbreviations: C, cooperativeness; HA, harm avoidance; MADRS, Montgomery–Åsberg Depression Rating Scale; NS, novelty-seeking; P, persistence; RD, reward dependence; SD, self-directedness; ST, self-transcendence; TCI, Temperament and Character Inventory.

Table 2 Responders and correlations between paroxetine concentration and MADRS-improvement rate by patient scores in each TCI dimension

	MADRS, week 0	P-value	n (responders, nonresponders)	P-value	Correlation coefficients	P-value
Entire	39.8±9.2	–	62 (43, 19)	–	−0.304	0.016*
NS
Low	41.7±8.9	0.137	29 (19, 10)	0.539	−0.370	0.048*
High	38.2±9.2		33 (24, 9)		−0.263	0.139
HA
Low	38.2±10.0	0.232	26 (20, 6)	0.272	−0.072	0.729
High	41.0±8.5		36 (23, 13)		−0.514	0.001**
RD
Low	41.6±6.9	0.142	29 (18, 11)	0.243	−0.420	0.023*
High	38.3±10.6		33 (25, 8)		−0.178	0.321
P
Low	38.6±9.4	0.238	33 (24, 9)	0.539	−0.286	0.107
High	41.3±8.8		29 (19, 10)		−0.338	0.073
SD
Low	43.4±7.4	0.004**	28 (18, 10)	0.432	−0.496	0.007**
High	36.9±9.5		34 (25, 9)		−0.253	0.148
C
Low	41.9±10.1	0.116	28 (16, 12)	0.058	−0.223	0.255
High	38.2±8.1		34 (27, 7)		−0.324	0.062
ST
Low	37.0±10.4	0.033*	27 (16, 11)	0.130	−0.293	0.138
High	42.0±7.6		35 (27, 8)		−0.242	0.162

Notes:

* P<0.05;

** P<0.01.

Abbreviations: C, cooperativeness; HA, harm avoidance; MADRS, Montgomery–Åsberg Depression Rating Scale; NS, novelty-seeking; P, persistence; RD, reward dependence; SD, self-directedness; ST, self-transcendence; TCI, Temperament and Character Inventory.

Table 3 Responder rates and correlations between paroxetine concentration and MADRS-improvement rate in patients with/without combined characteristics

	MADRS, week 0	P-value	n (responders, nonresponders)	P-value	Correlation coefficients	P-value
Low NS–high HA
Applicable	42.5±7.3	0.095	22 (14, 8)	0.469	−0.477	0.025*
Not applicable	38.4±9.8		40 (29, 11)		−0.233	0.147
Low NS–low RD
Applicable	41.9±8.0	0.274	15 (11, 4)	0.701	−0.473	0.075
Not applicable	39.2±9.5		47 (32, 15)		−0.297	0.042*
Low NS–low SD
Applicable	45.2±6.8	0.008**	15 (10, 5)	0.795	−0.547	0.035*
Not applicable	38.1±9.2		47 (33, 14)		−0.247	0.094
High HA–low RD
Applicable	41.2±6.8	0.451	18 (11, 7)	0.368	−0.472	0.048*
Not applicable	39.3±10.0		44 (32, 12)		−0.220	0.152
High HA–low SD
Applicable	43.4±7.8	0.026*	21 (13, 8)	0.362	−0.633	0.002**
Not applicable	38.0±9.3		41 (30, 11)		−0.196	0.219
Low RD–low SD
Applicable	42.4±6.5	0.201	16 (9, 7)	0.187	−0.541	0.031*
Not applicable	39.0±9.8		46 (34, 12)		−0.251	0.093

Notes: Applicable, subjects with each combined characteristic; not applicable, subjects without each combined characteristic;

* P<0.05;

** P<0.01.

Abbreviations: C, cooperativeness; HA, harm avoidance; MADRS, Montgomery–Åsberg Depression Rating Scale; NS, novelty-seeking; P, persistence; RD, reward dependence; SD, self-directedness; ST, self-transcendence.